No connection

Search Results

AHG vs BHC

AHG
Akso Health Group
BEARISH
Price
$2.50
Market Cap
$2.14B
Sector
Healthcare
AI Confidence
85%
BHC
Bausch Health Companies Inc.
BEARISH
Price
$5.91
Market Cap
$2.19B
Sector
Healthcare
AI Confidence
78%

Valuation

P/E Ratio
AHG
--
BHC
6.79
Forward P/E
AHG
--
BHC
1.41
P/B Ratio
AHG
10.82
BHC
-3.88
P/S Ratio
AHG
144.3
BHC
0.22
EV/EBITDA
AHG
-4387.63
BHC
6.95

Profitability

Gross Margin
AHG
1.0%
BHC
70.67%
Operating Margin
AHG
-20.54%
BHC
26.74%
Profit Margin
AHG
0.0%
BHC
3.61%
ROE
AHG
-68.29%
BHC
563.16%
ROA
AHG
-1.42%
BHC
4.83%

Growth

Revenue Growth
AHG
0.9%
BHC
6.8%
Earnings Growth
AHG
--
BHC
--

Financial Health

Debt/Equity
AHG
0.01
BHC
59.11
Current Ratio
AHG
1.53
BHC
1.3
Quick Ratio
AHG
1.19
BHC
0.78

Dividends

Dividend Yield
AHG
--
BHC
--
Payout Ratio
AHG
0.0%
BHC
0.0%

AI Verdict

AHG BEARISH

AHG's Piotroski F-Score of 5/9 indicates a stable but not strong financial position, with significant red flags in profitability and cash flow. The company reports a 0.00% profit margin, negative ROE of -68.29%, and a gross margin of just 1.00%, signaling deep operational inefficiencies. Despite a low debt/equity ratio and decent liquidity, the absence of positive earnings, free cash flow, and a lack of dividend support undermine long-term sustainability. The stock's price performance is driven by speculative momentum rather than fundamentals, with a Price/Sales of 144.30 far exceeding sector averages and no intrinsic value support.

Strengths
Low debt/equity ratio (0.01) indicates minimal financial leverage risk
Current ratio of 1.53 and quick ratio of 1.19 suggest adequate short-term liquidity
Recent price surge (85.2% in 1 week) reflects strong short-term market momentum
Risks
Negative ROE (-68.29%) and ROA (-1.42%) indicate severe capital inefficiency and losses
0.00% profit margin and -20.54% operating margin reveal fundamental business model flaws
No free cash flow or operating cash flow data available, raising liquidity sustainability concerns
BHC BEARISH

The deterministic health scores paint a concerning picture, with a Piotroski F-Score of 4/9 indicating marginal financial stability and no Altman Z-Score available to confirm solvency, raising red flags. Despite a low P/E of 6.79 and forward P/E of 1.41 suggesting potential undervaluation, the negative Price/Book ratio (-3.88) implies serious equity deficiencies or accumulated losses. Strong operating and gross margins contrast sharply with a sky-high Debt/Equity ratio of 59.11, indicating extreme leverage risk. Insider selling, weak technical trend (0/100), and a 5-year price decline of 78.1% further underscore investor skepticism and structural challenges.

Strengths
High gross margin (70.67%) indicating strong pricing power or cost control in core operations
Solid operating margin (26.74%) relative to sector average
Revenue growth of 6.80% YoY in a competitive specialty pharma environment
Risks
Extremely high Debt/Equity ratio of 59.11, far above sector average of 2.26, indicating severe financial leverage and refinancing risk
Piotroski F-Score of 4/9 signals weak financial health, particularly concerning given lack of Altman Z-Score for validation
Negative Price/Book ratio (-3.88) suggests book value is negative, a sign of accumulated losses or negative equity

Compare Another Pair

AHG vs BHC: Head-to-Head Comparison

This page compares Akso Health Group (AHG) and Bausch Health Companies Inc. (BHC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile